‘Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta‐analysis’

@article{Satapathy2019PeptideRR,
  title={‘Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta‐analysis’},
  author={Swayamjeet Satapathy and B. Mittal and A. Bhansali},
  journal={Clinical Endocrinology},
  year={2019},
  volume={91},
  pages={718 - 727}
}
  • Swayamjeet Satapathy, B. Mittal, A. Bhansali
  • Published 2019
  • Medicine
  • Clinical Endocrinology
    • Inoperable and metastatic pheochromocytomas and paragangliomas (PPGLs) present a therapeutic challenge with current treatment options being limited to radiolabelled meta‐iodo‐benzyl‐guanidine (MIBG) and systemic chemotherapy. Peptide receptor radionuclide therapy (PRRT) seems to be a promising option for these patients with few studies reporting favourable response. This systematic review was conducted to evaluate the efficacy and safety of PRRT in patients with advanced PPGLs. 
    View on Wiley
    ncbi.nlm.nih.gov
    8 Citations
    Background Citations
    1
    8 Citations
    Citation Type

    Citation Type

    177Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma
    • PDF
    131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma
    Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma
    • PDF
    131I-MIBG negative progressive symptomatic metastatic paraganglioma: response and outcome with 177Lu-DOTATATE peptide receptor radionuclide therapy
    HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop
    • 7
    Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma
    Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on endocrine hypertension of the European society of hypertension.
    • 7
    The difficulties in the diagnosis and treatment of malignant paraganglioma of the urinary bladder.

    References

    SHOWING 1-10 OF 43 REFERENCES
    Peptide Receptor Radionuclide Treatment and (131)I‐MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas
    • 30
    • PDF
    131I‐MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta‐analysis
    • 77
    Peptide receptor radionuclide therapy for metastatic paragangliomas
    • 18
    Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta‐analysis
    • 76
    Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma
    • 55
    • PDF
    Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra‐adrenal paragangliomas
    • 90
    Recent advances in the management of malignant pheochromocytoma and paraganglioma : focus on tyrosine kinase and hypoxia-inducible factor inhibitors
    • 1
    Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    • 4
    • PDF
    Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors
    • 15
    • PDF
    Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives
    • 14